Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 8/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCND2 | P30279 | 1/20 | 0.51 |
| ▸ | CCND3 | P30281 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494517 | 0.87 | MAP4K1 (0.62) | STK17ACDK4CCND1CCND2CCND3 | |
| SCHEMBL1634382 | 0.84 | IGF1R (0.59) | MAPTMAPK1IGF1RMAPK10SYK | |
| SCHEMBL3503540 | 0.83 | MAPK10 (0.54) | MAPTMAPK1IGF1RMAPK10SYK | |
| SCHEMBL3503353 | 0.83 | JAK2 (0.63) | MAPTMAPK1IGF1RMAPK10SYK | |
| SCHEMBL13363164 | 0.83 | EPHB4 (0.50) | MAPTMAPK1AHRHTTIGF1R | |
| SCHEMBL3041756 | 0.82 | MYLK4 (0.62) | MAPK10SYKMYLK4STK17A | |
| SCHEMBL1868375 | 0.81 | SYK (0.56) | MAPK10SYKSTAT6 | |
| SCHEMBL789790 | 0.81 | MAPT (0.59) | MAPTMAPK1AHRHTTIGF1R | |
| SCHEMBL1634550 | 0.80 | CDK1 (0.59) | MAPTMAPK1IGF1RMAPK10SYK | |
| SCHEMBL1873404 | 0.79 | CDK1 (0.63) | MAPTMAPK1MAPK10SYKTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | claimed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | claimed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPT 2829/4885MAPK1 233/4885AHR 4009/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | MAPT 2316/4885MAPK1 196/4885AHR 3305/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | MAPT 4079/4885MAPK1 63/4885AHR 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.